Cargando…

NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer

N-myc downstream-regulated gene 1 (NDRG1) is a key regulator that interacts with many classic tumor signaling pathways, including some molecules downstream of the epidermal growth factor receptor (EGFR). However, whether NDRG1 is involved in the mechanism of resistance to cetuximab (CTX), the first...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Guang, Huang, Ling, Jia, Hongtao, Aikemu, Batuer, Zhang, Sen, Shao, Yanfei, Hong, Hiju, Yesseyeva, Galiya, Wang, Chenxing, Li, Shuchun, Sun, Jing, Zheng, Minhua, Ma, Junjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516652/ https://www.ncbi.nlm.nih.gov/pubmed/34385595 http://dx.doi.org/10.1038/s41388-021-01962-8

Ejemplares similares

NDRG1 regulates Filopodia-induced Colorectal Cancer invasiveness via modulating CDC42 activity
por: Aikemu, Batuer, et al.
Publicado: (2021)

Exploring the relationship between lactate metabolism and immunological function in colorectal cancer through genes identification and analysis
por: Zhang, Enkui, et al.
Publicado: (2023)

Prefoldin subunits (PFDN1–6) serve as poor prognostic markers in gastric cancer
por: Yesseyeva, Galiya, et al.
Publicado: (2020)

An Original Ferroptosis-Related Gene Signature Effectively Predicts the Prognosis and Clinical Status for Colorectal Cancer Patients
por: Shao, Yanfei, et al.
Publicado: (2021)

Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer
por: Wang, Chenxing, et al.
Publicado: (2022)

ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer: ACACB is a biomarker for CTX therapy in metastatic CRC
por: Hong, Hi-Ju, et al.
Publicado: (2022)

Comprehensive exploration of tumor immune microenvironment feature and therapeutic response in colorectal cancer based on a novel immune-related long non-coding RNA prognostic signature
por: Zhou, Xueliang, et al.
Publicado: (2022)

Comprehensive Analysis of Ferroptosis-Related Markers for the Clinical and Biological Value in Gastric Cancer
por: Shao, Yanfei, et al.
Publicado: (2021)

Artificial Intelligence in Decision-Making for Colorectal Cancer Treatment Strategy: An Observational Study of Implementing Watson for Oncology in a 250-Case Cohort
por: Aikemu, Batuer, et al.
Publicado: (2021)

PKCδ promotes the invasion and migration of colorectal cancer through c-myc/NDRG1 pathway
por: Jia, Hong-tao, et al.
Publicado: (2023)

N-myc downstream-regulated gene 1 inhibits the proliferation of colorectal cancer through emulative antagonizing NEDD4-mediated ubiquitylation of p21
por: Zhang, Sen, et al.
Publicado: (2019)

Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer
por: Zhang, Enkui, et al.
Publicado: (2023)

Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer
por: Yu, Chaoran, et al.
Publicado: (2018)

Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer
por: Yang, Guang, et al.
Publicado: (2021)

Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy
por: Zhang, Enkui, et al.
Publicado: (2023)

Identification of key genes and pathways involved in microsatellite instability in colorectal cancer
por: Yu, Chaoran, et al.
Publicado: (2019)

Identification of Key Genes and Pathways Involved in Circulating Tumor Cells in Colorectal Cancer
por: Pan, Ruijun, et al.
Publicado: (2022)

The Metastasis Suppressor, N-myc Downregulated Gene 1 (NDRG1), Is a Prognostic Biomarker for Human Colorectal Cancer
por: Mao, Zhihai, et al.
Publicado: (2013)

Characterization of the prognostic values of the NDRG family in gastric cancer
por: Yu, Chaoran, et al.
Publicado: (2019)

Structured training curricula for robotic colorectal surgery in China: does laparoscopic experience affect training effects?
por: Shu, Duohuo, et al.
Publicado: (2023)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Impact of Cuproptosis-related markers on clinical status, tumor immune microenvironment and immunotherapy in colorectal cancer: A multi-omic analysis
por: Shao, Yanfei, et al.
Publicado: (2023)

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
por: Cappuzzo, F, et al.
Publicado: (2008)

The metastasis suppressor, NDRG1, inhibits “stemness” of colorectal cancer via down-regulation of nuclear β-catenin and CD44
por: Wangpu, Xiongzhi, et al.
Publicado: (2015)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer
por: Luo, Maochao, et al.
Publicado: (2021)

NDRG2 gene copy number is not altered in colorectal carcinoma
por: Lorentzen, Anders, et al.
Publicado: (2017)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab
por: Liu, Shujie, et al.
Publicado: (2022)

Expression of NDRG2 in Human Colorectal Cancer and its Association with Prognosis
por: Chen, Wenjing, et al.
Publicado: (2019)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014)

Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
por: Goulet, Dennis R., et al.
Publicado: (2022)

MORC2 promotes development of an aggressive colorectal cancer phenotype through inhibition of NDRG1
por: Liu, Jiao, et al.
Publicado: (2018)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
por: Spindler, Karen-Lise G, et al.
Publicado: (2011)

NDRG1 is expressed in human granulosa cells: An implicative role of NDRG1 in the ovary
por: Nishigaki, Akemi, et al.
Publicado: (2022)

Clinical Diagnostic and Prognostic Potential of NDRG1 and NDRG2 in Hepatocellular Carcinoma Patients
por: Xu, Shaohua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p5bvkttbj2qs2h9tn5kojl8ner